Replies to post #62697 on NanoViricides Inc. (NNVC)

[Puffer]

you are assuming an efficient market, often not the case with penny stocks where retail investors control the float.

There are 3 key factors that are not priced into the stock here --

1. The "drug" (flucide) does not alter cell function thus rendering the odds of toxicity much lower than your typical drug.

2. Human clinical trials likely less than 12 months away.

3. Due to the self-limiting nature of the flu, those clinical trials, all phases, can be completed in total in a few months, unlike your typical cancer drug, for example, that can take more like 7 yrs to complete trials.

This is all complicated somewhat by the situation with Seaside which continues to dump stock into the market for short term profit, unrelated to the fundamentals of the company.... another reason why it is not efficiently priced here.

[BonelessCat]

What you post is also typical of posts here. I just want to point that out. I've read your post repeatedly for 6 years. Only the posting aliases change.

[Echo20]

jg35

Where do you get only 13% possibility for FLUCIDE passing Phase One Clinical Trial?

There were some tests done at LSU with larger animals.

Where are those results?

Were HUMANIZED MICE USED in testing FLUCIDE?

Echo20